These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 15828237)

  • 1. [Polycystic ovary syndrome].
    Ohnaka K; Takayanagi R
    Nihon Rinsho; 2005 Apr; 63(4):681-6. PubMed ID: 15828237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Insulin sensitizers in polycystic ovary syndrome.
    Pasquali R; Gambineri A
    Front Horm Res; 2013; 40():83-102. PubMed ID: 24002407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Troglitazone for treatment of polycystic ovary syndrome].
    Sanaka M; Iwamoto Y
    Nihon Rinsho; 2000 Feb; 58(2):465-70. PubMed ID: 10707578
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thiazolidinediones for the therapeutic management of polycystic ovary syndrome : impact on metabolic and reproductive abnormalities.
    Elkind-Hirsch KE
    Treat Endocrinol; 2006; 5(3):171-87. PubMed ID: 16677059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of the insulin sensitizer pioglitazone on insulin resistance, hyperandrogenism, and ovulatory dysfunction in women with polycystic ovary syndrome.
    Brettenthaler N; De Geyter C; Huber PR; Keller U
    J Clin Endocrinol Metab; 2004 Aug; 89(8):3835-40. PubMed ID: 15292314
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin-sensitizing agents in the treatment of polycystic ovary syndrome: an update.
    Katsiki N; Hatzitolios AI
    Curr Opin Obstet Gynecol; 2010 Dec; 22(6):466-76. PubMed ID: 20724929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug insight: insulin-sensitizing drugs in the treatment of polycystic ovary syndrome--a reappraisal.
    Dunaif A
    Nat Clin Pract Endocrinol Metab; 2008 May; 4(5):272-83. PubMed ID: 18364705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.
    Dunaif A; Scott D; Finegood D; Quintana B; Whitcomb R
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3299-306. PubMed ID: 8784087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insulin-lowering agents in the management of polycystic ovary syndrome.
    De Leo V; la Marca A; Petraglia F
    Endocr Rev; 2003 Oct; 24(5):633-67. PubMed ID: 14570747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insulin-sensitizing agents in polycystic ovary syndrome.
    Pasquali R; Gambineri A
    Eur J Endocrinol; 2006 Jun; 154(6):763-75. PubMed ID: 16728533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome.
    Stabile G; Borrielli I; Artenisio AC; Bruno LM; Benvenga S; Giunta L; La Marca A; Volpe A; Pizzo A
    J Pediatr Adolesc Gynecol; 2014 Jun; 27(3):177-82. PubMed ID: 24814528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rosiglitazone in obese women with polycystic ovary syndrome and severe insulin resistance.
    Sepilian V; Nagamani M
    J Clin Endocrinol Metab; 2005 Jan; 90(1):60-5. PubMed ID: 15483106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Polycystic ovary syndrome, metabolic syndrome, cardiovascular risk and the role of insulin sensitizing agents].
    Silva Rdo C; Pardini DP; Kater CE
    Arq Bras Endocrinol Metabol; 2006 Apr; 50(2):281-90. PubMed ID: 16767294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impaired insulin-stimulated phosphorylation of Akt and AS160 in skeletal muscle of women with polycystic ovary syndrome is reversed by pioglitazone treatment.
    Højlund K; Glintborg D; Andersen NR; Birk JB; Treebak JT; Frøsig C; Beck-Nielsen H; Wojtaszewski JF
    Diabetes; 2008 Feb; 57(2):357-66. PubMed ID: 17977950
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome.
    Hahn S; Fingerhut A; Khomtsiv U; Khomtsiv L; Tan S; Quadbeck B; Herrmann BL; Knebel B; Müller-Wieland D; Mann K; Janssen OE
    Clin Endocrinol (Oxf); 2005 May; 62(5):573-9. PubMed ID: 15853827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.
    Ehrmann DA; Schneider DJ; Sobel BE; Cavaghan MK; Imperial J; Rosenfield RL; Polonsky KS
    J Clin Endocrinol Metab; 1997 Jul; 82(7):2108-16. PubMed ID: 9215280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thiazolinedione treatment in PCOS--an update.
    Glintborg D; Andersen M
    Gynecol Endocrinol; 2010 Nov; 26(11):791-803. PubMed ID: 20528570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is metformin a primary ovulatory agent in patients with polycystic ovary syndrome?
    Cheang KI; Sharma ST; Nestler JE
    Gynecol Endocrinol; 2006 Nov; 22(11):595-604. PubMed ID: 17145645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leptin concentrations in the polycystic ovary syndrome.
    Mantzoros CS; Dunaif A; Flier JS
    J Clin Endocrinol Metab; 1997 Jun; 82(6):1687-91. PubMed ID: 9177364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications.
    Nestler JE
    Semin Reprod Endocrinol; 1997 May; 15(2):111-22. PubMed ID: 9165656
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.